Proposal for MitoQ (mitoquinone; Aviva Systems Biology Cat# OX1125)

Overview of Therapeutic Candidate:
MitoQ (mitoquinone) is a synthetic derivative of coenzyme Q10 (CoQ10) engineered for mitochondria‐targeted antioxidant therapy. It is produced by conjugating a ubiquinone moiety to a lipophilic triphenylphosphonium cation, which exploits the mitochondrial membrane potential for preferential uptake into mitochondria. In so doing, MitoQ overcomes the suboptimal absorption and distribution of native CoQ10 by ensuring that the antioxidant is delivered directly into the inner mitochondrial membrane where reactive oxygen species (ROS) are predominantly generated. MitoQ belongs to the class of mitochondria‐targeted antioxidants—a group that includes other compounds like idebenone and SkQ1—and is designed to quench lipid‐derived ROS, stabilize mitochondrial membranes, and maintain mitochondrial bioenergetics. This class of therapeutic compounds has been widely investigated across biomedical research to counteract oxidative stress–mediated cellular dysfunction in various diseases. The synthesis of MitoQ involves standard organic coupling procedures to attach the triphenylphosphonium cation to the CoQ10 derivative, yielding a molecule that is both chemically stable and capable of systemic administration while achieving intracellular and intramitochondrial accumulation (Osborne et al., 2014; ClinicalTrials.gov, n.d.).

Therapeutic History:
MitoQ has undergone extensive preclinical and clinical evaluation in various conditions characterized by mitochondrial oxidative stress. Historically, MitoQ has been evaluated in clinical trials for conditions such as fatigue in multiple sclerosis (Yadav, 2018) and for mitigating vascular dysfunction in aging populations (University of Colorado, Denver, 2023; Al-Naggar, 2024), thereby supporting its safety profile and demonstrating measurable tissue accumulation following oral dosing (ClinicalTrials.gov, n.d.). Although MitoQ itself has not been directly approved nor widely clinically tested for dry age‐related macular degeneration (AMD), its therapeutic class has been explored in analogous conditions where mitochondrial dysfunction plays a central role, such as in diabetic retinopathy and other retinal degenerative diseases. Preclinical studies using rodent models have shown that mitochondria‐targeted antioxidants can improve retinal function and reduce drusen‐like deposits. In several rodent models of retinal degeneration, antioxidants similar in mechanism to MitoQ have provided protection of retinal pigment epithelium (RPE) cells and preserved photoreceptor function (Han, 2018; ClinicalTrials.gov, n.d.). In addition, compounds such as SkQ1 have been used to mitigate AMD‐like retinopathy in OXYS rats (Muraleva et al., 2014); although these studies do not evaluate MitoQ directly, they underscore the promise of targeting mitochondrial ROS for treating retinal degenerations. Thus, while the direct therapeutic history of MitoQ in dry AMD remains to be fully established, the cumulative evidence from its use in other oxidative stress–related disorders and its ability to produce significant tissue levels in the retina support its further evaluation in dry AMD (ClinicalTrials.gov, n.d.; Ji et al., 2021).

Mechanism of Action:
MitoQ’s therapeutic rationale hinges on its ability to selectively accumulate within mitochondria, where it acts as a potent antioxidant and modulator of mitochondrial quality control. Its lipophilic triphenylphosphonium component allows for a several‐hundred‐fold accumulation within the mitochondrial matrix, driven by the negative mitochondrial membrane potential. Once inside the mitochondria, the ubiquinone moiety of MitoQ is reduced by complex II of the electron transport chain (ETC) to its active ubiquinol form. This reduced form then functions to detoxify reactive oxygen species, particularly lipid peroxyl radicals generated during oxidative processes, thereby preventing lipid peroxidation of mitochondrial membranes. Consequently, MitoQ preserves mitochondrial dynamics by maintaining membrane integrity and normal electron flow through the ETC, which is critical for ATP production and overall cellular bioenergetics (Osborne et al., 2014; Ji et al., 2021).

On the molecular level, the reduction in mitochondrial ROS exerts downstream effects that include reduced priming of the NLRP3 inflammasome—a multiprotein complex that, when activated, triggers inflammatory cascades known to contribute to RPE degeneration and dry AMD pathogenesis. By mitigating ROS levels, MitoQ decreases inadvertent activation of the NLRP3 inflammasome, thereby dampening chronic inflammation within the retina (Datta et al., 2023; Brooks et al., 2023). Furthermore, reduced oxidative stress is anticipated to have a positive effect on cellular autophagy; RPE cells require efficient autophagic clearance of damaged cellular components and photoreceptor outer segments (POS) to maintain homeostasis. MitoQ, by safeguarding mitochondrial function and preventing excessive ROS-induced damage, supports lysosomal integrity and enhances autophagic flux, which is essential for proper POS phagocytosis (Zhang et al., 2023; Brooks et al., 2023). In addition, the preservation of mitochondrial dynamics, including balanced fission and fusion events, is critical for the maintenance of cellular energy levels and for initiating mitophagy—the selective removal of damaged mitochondria—which has been shown to be impaired in aging RPE (Datta et al., 2023; Ji et al., 2021). In summary, MitoQ’s molecular interactions range from direct ROS scavenging to the modulation of inflammatory and autophagic pathways that are directly implicated in dry AMD pathology (ClinicalTrials.gov, n.d.; Osborne et al., 2014).

Expected Effect:
Based on the described mechanism of action, the expected therapeutic effect of MitoQ in dry AMD is multifaceted. First, by accumulating in RPE mitochondria and neutralizing lipid‐derived ROS, MitoQ is anticipated to reduce oxidative damage that would otherwise compromise mitochondrial membrane potential and lead to mitochondrial dysfunction. This is critical because diseased RPE cells in dry AMD display elevated ROS levels that destabilize mitochondrial membranes and reduce ATP production (Han, 2018; ClinicalTrials.gov, n.d.). Second, the reduction in mitochondrial ROS is expected to prevent the priming of the NLRP3 inflammasome. Since excessive activation of the NLRP3 inflammasome is linked to chronic inflammation and subsequent degeneration within the RPE, reducing its activation should attenuate inflammatory signaling cascades and slow the progression of AMD‐associated atrophy (Datta et al., 2023; Brooks et al., 2023). Third, the maintenance of mitochondrial dynamics and the preservation of autophagic efficacy are predicted to enhance the RPE’s capacity for photoreceptor outer segment (POS) phagocytosis. Efficient POS clearance is essential for retinal homeostasis, and its failure is a hallmark in the development of drusen and other pathologic deposits typical of dry AMD (Ji et al., 2021; Zhang et al., 2023). Moreover, enhanced autophagy and lysosomal integrity are crucial for the clearance of oxidatively‐damaged organelles and aggregated proteins, thus helping to maintain cellular health in an environment of chronic oxidative stress (Brooks et al., 2023; Chen et al., 2024). Preclinical evidence in rodent models further supports that mitochondrial-targeted antioxidants can improve retinal function and reduce drusen-like deposits, setting a strong precedent for the utility of MitoQ in preserving RPE function (ClinicalTrials.gov, n.d.; Han, 2018). On an assay level, one would expect to observe reduced markers of oxidative stress (e.g., lipid peroxidation products), lower levels of NLRP3 inflammasome activation (as measured by caspase-1 activity and IL-1β secretion), improvement in mitochondrial respiratory function, and enhanced autophagic flux when MitoQ is tested in RPE cell cultures or preclinical animal models of dry AMD (Datta et al., 2023; Brooks et al., 2023).

Overall Evaluation:
In our comprehensive review, MitoQ emerges as a promising therapeutic candidate for dry AMD based on its targeted mechanism, supportive preclinical evidence, and favorable pharmacokinetic profile demonstrated in other conditions. One strength of MitoQ is its ability to accumulate selectively in mitochondria, where it effectively reduces lipid-derived ROS and thus addresses the upstream initiators of the cascade leading to mitochondrial dysfunction, inflammasome activation, and compromised autophagy in the RPE (Osborne et al., 2014; Ji et al., 2021). The compound’s established safety in clinical trials for other indications (ClinicalTrials.gov, n.d.) and measurable tissue uptake provide additional support for its repurposing in ocular diseases, including dry AMD (Datta et al., 2023; Ji et al., 2021). Furthermore, by mitigating the activation of the NLRP3 inflammasome, MitoQ targets one of the crucial inflammatory mechanisms implicated in RPE degeneration, which may translate into reduced chronic inflammation and slower disease progression. Its role in supporting autophagic and lysosomal integrity is particularly relevant given that impaired phagocytosis of photoreceptor outer segments is a known contributor to drusen formation and RPE dysfunction (Zhang et al., 2023; Brooks et al., 2023).

However, several weaknesses or challenges remain. Direct clinical evidence of MitoQ’s effects in dry AMD is currently lacking; most of the supportive data are derived from analogous preclinical studies and the use of similar compounds in related retinal models. While rodent models and in vitro studies offer encouraging results regarding mitochondrial antioxidants, the translation of these findings into a robust clinical benefit in human AMD remains to be demonstrated. Additionally, the complex etiology of dry AMD—which involves genetic predisposition, environmental stresses, and multiple cellular pathways—suggests that a single‐target approach, even one as central as mitochondrial ROS reduction, may need to be combined with other therapeutic strategies to achieve a significant clinical effect (ClinicalTrials.gov, n.d.; Al-Naggar, 2024). Moreover, potential off-target effects and the long-term safety of chronic MitoQ administration in the retina must be thoroughly evaluated, despite its favorable safety profile in systemic applications (ClinicalTrials.gov, n.d.; Han, 2018; Datta et al., 2023; Ji et al., 2021).

Overall, the evidence from mitochondrial biology, preclinical rodent models, and parallel human clinical trials in other conditions provide a compelling rationale to advance MitoQ for dry AMD. Its strengths lie in its targeted mechanism, established pharmacokinetics, and the centrality of mitochondrial dysfunction in AMD pathogenesis, whereas the main weakness is the current gap in direct clinical validation for AMD. Given the significant unmet medical need in dry AMD, MitoQ represents a promising candidate that merits further investigation through rigorous preclinical studies in retinal models followed by targeted clinical trials to assess efficacy and safety in AMD patients (ClinicalTrials.gov, n.d.; Han, 2018; Datta et al., 2023; Ji et al., 2021).

References
Al-Naggar, I. (2024). Testing MitoQ on lower urinary tract symptoms in older women with metabolic syndrome (NCT06351683). ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT06351683

Brooks, C. D., Kodati, B., Stankowska, D. L., & Krishnamoorthy, R. R. (2023). Role of mitophagy in ocular neurodegeneration. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2023.1299552

Chen, X., Xu, Y., Ju, Y., & Gu, P. (2024). Metabolic regulation of endothelial cells: A new era for treating wet age-related macular degeneration. International Journal of Molecular Sciences, 25, 5926. https://doi.org/10.3390/ijms25115926

ClinicalTrials.gov. (n.d.). Search for MitoQ OR mitoquinone AND (macular degeneration OR AMD OR retina). Retrieved from https://clinicaltrials.gov/ct2/results?term=MitoQ+OR+mitoquinone+AND+%28macular+degeneration+OR+AMD+OR+retina%29

Datta, S., Cano, M., Satyanarayana, G., Liu, T., Wang, L., Wang, J., Cheng, J., Itoh, K., Sharma, A., Bhutto, I., Kannan, R., Qian, J., Sinha, D., & Handa, J. T. (2023). Mitophagy initiates retrograde mitochondrial-nuclear signaling to guide retinal pigment cell heterogeneity. Autophagy, 19, 966–983. https://doi.org/10.1080/15548627.2022.2109286

Han, W. H. (2018). Changes in retinal mitochondrial function in ocular diseases and a potential treatment using near-infrared light. [Journal unknown].

Ji, M. H., Kreymerman, A., Belle, K., Ghiam, B. K., Muscat, S. R., Mahajan, V. B., Enns, G. M., Mercola, M., & Wood, E. H. (2021). The present and future of mitochondrial-based therapeutics for eye disease. Translational Vision Science & Technology, 10(8), Article 4. https://doi.org/10.1167/tvst.10.8.4

Muraleva, N. A., Kozhevnikova, O. S., Zhdankina, A. A., Stefanova, N. A., Karamysheva, T. V., Fursova, A. Z., & Kolosova, N. G. (2014). The mitochondria-targeted antioxidant SkQ1 restores αB-crystallin expression and protects against AMD-like retinopathy in OXYS rats. Cell Cycle, 13(21), 3499–3505. https://doi.org/10.4161/15384101.2014.958393

Osborne, N. N., Núñez Álvarez, C., & del Olmo Aguado, S. (2014). Targeting mitochondrial dysfunction as in aging and glaucoma. Drug Discovery Today, 19(10), 1613–1622. https://doi.org/10.1016/j.drudis.2014.05.010

University of Colorado, Denver. (2023). MitoQ and exercise effects on vascular health (NCT05686967). ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT05686967

Yadav, V. (2018). MitoQ for fatigue in multiple sclerosis (NCT03166800). ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT03166800

Zhang, S.-M., Fan, B., Li, Y.-L., Zuo, Z.-Y., & Li, G.-Y. (2023). Oxidative stress-involved mitophagy of retinal pigment epithelium and retinal degenerative diseases. Cellular and Molecular Neurobiology, 43, 3265–3276. https://doi.org/10.1007/s10571-023-01383-z
